Valuation: Apogee Therapeutics, Inc.

Market Cap 10.12B 8.76B 8.18B 7.5B 14.11B 963B 14.33B 95.94B 37.66B 483B 38.02B 37.18B 1,597B P/E 2026 *
-31.2x
P/E 2027 * -24.2x
Enterprise Value 9.14B 7.91B 7.39B 6.78B 12.74B 870B 12.95B 86.66B 34.01B 436B 34.34B 33.59B 1,442B EV / Sales 2026 *
1,006x
EV / Sales 2027 * 751x
Free-Float
94.51%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Apogee Therapeutics, Inc.

1 day+0.26%
1 week+0.56%
Current month+0.56%
1 month+1.19%
3 months+62.40%
6 months+116.65%
Current year+78.64%
1 week 134.03
Extreme 134.03
134.88
1 month 133.36
Extreme 133.36
134.88
Current year 60.35
Extreme 60.35
134.88
1 year 34.4
Extreme 34.395
134.88
3 years 14.19
Extreme 14.19
134.88
5 years 14.19
Extreme 14.19
134.88
10 years 14.19
Extreme 14.19
134.88
Manager TitleAgeSince
Chief Executive Officer 36 01/09/2022
Director of Finance/CFO 60 01/01/2023
Chief Tech/Sci/R&D Officer - 01/05/2023
Director TitleAgeSince
Director/Board Member 54 22/06/2023
Director/Board Member 62 01/06/2023
Director/Board Member 36 01/06/2023
Date Insider Type Main position Quantity % Market Cap.
24/7/26 Don

Chief Financial Officer

-15,000 0.0268%
14/7/26 Don

Chief Technology Officer

-8,000 0.0143%
10/7/26 Don

Chief Executive Officer

-75,046 0.1340%
Change 5-day change 1-year change 3-year change Capi.($)
+0.26%+0.56%+281.01%+528.33% 10.12B
+0.99%+1.78%+5.07%+16.49% 49.47B
+3.71%+9.40%+486.14%+579.98% 43.97B
+5.60%+10.21%+20.85%+81.78% 39.6B
+2.70%+1.57%+32.71%+9.07% 39.29B
+2.21%+6.75%+20.20%+54.40% 32.43B
+2.23%+4.71% - - 16.84B
+0.97%+2.35%+35.99%+124.45% 16.49B
-0.11%+2.41%+5.03%+20.47% 14.01B
+0.75%+15.04%+79.84%+29.70% 12.77B
Average +1.93%+5.74%+107.43%+160.52% 27.5B
Weighted average by Cap. +2.46%+5.90%+112.03%+153.95%

Financials

2026 *2027 *
Net sales 9.09M 7.86M 7.34M 6.74M 12.67M 865M 12.87M 86.16M 33.82M 434M 34.14M 33.39M 1.43B 12.5M 10.81M 10.1M 9.26M 17.42M 1.19B 17.7M 118M 46.5M 596M 46.94M 45.91M 1.97B
Net income -318M -275M -256M -235M -443M -30.22B -450M -3.01B -1.18B -15.15B -1.19B -1.17B -50.07B -416M -360M -336M -309M -580M -39.63B -590M -3.95B -1.55B -19.87B -1.56B -1.53B -65.67B
Net Debt -980M -847M -791M -726M -1.37B -93.22B -1.39B -9.28B -3.64B -46.72B -3.68B -3.6B -154B -740M -640M -598M -549M -1.03B -70.45B -1.05B -7.02B -2.75B -35.31B -2.78B -2.72B -117B
Logo Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.
Employees
261
Date Price Change Volume
07/08/26 USD 134.84 +0.26% 1,495,196
06/08/26 USD 134.49 +0.19% 1,232,938
05/08/26 USD 134.23 +0.03% 1,961,062
04/08/26 USD 134.19 +0.06% 2,377,913
03/08/26 USD 134.11 +0.01% 1,059,851
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
134.84USD
Average target price
130.53USD
Spread / Average Target
-3.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. APGE Stock